SAGE Therapeutics (NASDAQ: SAGE) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.
Risk and Volatility
SAGE Therapeutics has a beta of 3.07, suggesting that its share price is 207% more volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.09, suggesting that its share price is 109% more volatile than the S&P 500.
96.3% of SAGE Therapeutics shares are held by institutional investors. Comparatively, 37.0% of Corbus Pharmaceuticals shares are held by institutional investors. 6.1% of SAGE Therapeutics shares are held by insiders. Comparatively, 11.9% of Corbus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This is a breakdown of current ratings and target prices for SAGE Therapeutics and Corbus Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
SAGE Therapeutics presently has a consensus target price of $183.93, indicating a potential upside of 17.73%. Corbus Pharmaceuticals has a consensus target price of $25.75, indicating a potential upside of 312.00%. Given Corbus Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe Corbus Pharmaceuticals is more favorable than SAGE Therapeutics.
Valuation & Earnings
This table compares SAGE Therapeutics and Corbus Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|SAGE Therapeutics||N/A||N/A||-$270.12 million||($7.12)||-21.94|
|Corbus Pharmaceuticals||$2.44 million||146.34||-$32.42 million||($0.65)||-9.62|
Corbus Pharmaceuticals has higher revenue and earnings than SAGE Therapeutics. SAGE Therapeutics is trading at a lower price-to-earnings ratio than Corbus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This table compares SAGE Therapeutics and Corbus Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Corbus Pharmaceuticals beats SAGE Therapeutics on 8 of the 12 factors compared between the two stocks.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company’s next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company’s chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company’s product, anabasum is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Anabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing anabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.